Chimanlal Sons Medicare Products Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 23-10-2024
- Paid Up Capital ₹ 1.00 Cr
as on 23-10-2024
- Company Age 11 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 12.00 Cr
as on 23-10-2024
- Revenue 0.36%
(FY 2023)
- Profit 3.35%
(FY 2023)
- Ebitda 8.19%
(FY 2023)
- Net Worth 23.93%
(FY 2023)
- Total Assets -0.20%
(FY 2023)
About Chimanlal Sons Medicare Products
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 1.00 Cr.
The company currently has active open charges totaling ₹12.00 Cr.
Abhay Shah, Devendra Shah, Jayesh Shah, and Three other members serve as directors at the Company.
- CIN/LLPIN
U52100MH2013PTC239492
- Company No.
239492
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Jan 2013
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Chimanlal Sons Medicare Products?
Board Members(6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Abhay Shah  | Director | 09-Jan-2013 | Current |
| Devendra Shah | Director | 09-Jan-2013 | Current |
| Jayesh Shah | Director | 09-Jan-2013 | Current |
| Vipul Shah | Director | 14-Jan-2016 | Current |
| Rakesh Shah | Director | 14-Jan-2016 | Current |
| Shilpa Shah | Director | 14-Jan-2016 | Current |
Financial Performance of Chimanlal Sons Medicare Products.
Chimanlal Sons Medicare Products Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 0.36% increase. The company also saw a slight improvement in profitability, with a 3.35% increase in profit. The company's net worth Soared by an impressive increase of 23.93%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Chimanlal Sons Medicare Products?
In 2022, Chimanlal Sons Medicare Products had a promoter holding of 26.11% and a public holding of 73.89%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Crossroads Pharmacy Private LimitedActive 3 years 2 monthsDevendra Shah and Rakesh Shah are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 09 May 2019 | ₹12.00 Cr | Open |
How Many Employees Work at Chimanlal Sons Medicare Products?
Chimanlal Sons Medicare Products has a workforce of 20 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Chimanlal Sons Medicare Products, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Chimanlal Sons Medicare Products's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
